Clinical Trial Update: Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated Sorafenib in regional or metastatic urothelial cancer and was terminated with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urethral Cancer
• Urothelial Carcinoma of the Renal Pelvis
• Urothelial Carcinoma of the Ureter

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Bladder, Distal Urethral Cancer | Phase 2 | Status: TERMINATED | Results posted: 2011-04-04